The responses to antagonists of Ano1, Ca2+-activated chloride channels, and mitochondrial function inhibitors have been reported to vary among ICC subtypes (Sanders 2019; Hwang et al. 2009; Strege et al. 2015; Sung et al. 2016). This evidence concerns the gene ANO1 and intrahepatic cholangiocarcinoma.